Lavo Life Sciences

Drug development is full of costly surprises — especially when solid-state formulation issues surface late in the pipeline. Lavo Life Sciences is a VC-backed early-stage startup that uses AI to predict crystal structures of small molecule drugs, helping pharmaceutical teams de-risk their pipelines before it's too late.

Their web-based platform, Crystal Console, offers powerful computational tools including crystal structure analysis, virtual polymorph screening, and PXRD analysis. By catching formulation problems early and optimizing solid-state properties upfront, Lavo helps teams move faster and avoid the expensive surprises that derail late-stage development.